

Clovis Oncology, Inc.  
Form 8-K  
June 18, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **June 14, 2012**

**Clovis Oncology, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35347**  
(Commission  
File Number)

**90-0475355**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: Clovis Oncology, Inc. - Form 8-K

**2525 28<sup>th</sup> Street, Suite 100**  
**Boulder, Colorado**  
(Address of principal executive offices)  
Registrant's telephone number, including area code: **(303) 625-5000**

**80301**  
(Zip Code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The Annual Meeting of Shareholders (the Annual Meeting ) of Clovis Oncology Inc. (the Company ) was held on June 14, 2012. At the Annual Meeting, the shareholders of the Company voted on the following four proposals and cast their votes as described below.

**Proposal One**

The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company s Board of Directors (the Board ).

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Patrick J. Mahaffy	14,858,617	3,184,580	1,648,531
M. James Barrett	14,821,250	3,221,947	1,648,531
Thorlef Spickschen	14,822,996	3,220,201	1,648,531

**Proposal Two**

Proposal two was a management proposal to hold an advisory vote on the compensation of the Company s named executive officers, as described in the proxy materials. This proposal was approved.

<b>For</b>	<b>Against</b>	<b>Abstained</b>	<b>Broker Non-Votes</b>
13,637,114	4,388,603	17,480	1,648,531

**Proposal Three**

Proposal three was a management proposal to hold an advisory vote on the frequency of the stockholder advisory vote on the compensation of the Company s named executive officers, as described in the proxy materials. Three Years was approved.

<b>One Year</b>	<b>Two Years</b>	<b>Three Years</b>	<b>Abstained</b>	<b>Broker Non-Votes</b>
5,105,626	702,740	12,234,631	200	1,648,531

Based on these results, and consistent with the Company s recommendation, the Board has determined that the Company will hold an advisory vote on executive compensation every three years.

**Proposal Four**

Proposal four was a management proposal to ratify the appointment of Ernst & Young LLP as auditors of the Company for fiscal year 2012, as described in the proxy materials. This proposal was approved.

<b>For</b>	<b>Against</b>	<b>Abstained</b>
19,687,910	2,200	1,618

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

June 18, 2012

By: /s/ Erle T. Mast  
Name: Erle T. Mast  
Title: Executive Vice President and Chief Financial Officer

- 3 -